Literature DB >> 1318977

Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide, and cisplatin regimen for non-small-cell lung cancer.

J S Lee1, H I Libshitz, F V Fossella, W K Murphy, A C Pang, S M Lippman, D M Shin, I W Dimery, B S Glisson, W K Hong.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1318977     DOI： 10.1093/jnci/84.13.1039

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  4 in total

Review 1.  Promising new agents in the treatment of non-small cell lung cancer.

Authors:  M J Edelman; D R Gandara
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

2.  Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy.

Authors:  Ellen Koch; Sara K Story; Larisa J Geskin
Journal:  Leuk Lymphoma       Date:  2013-04-08

3.  Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro.

Authors:  T C Chou; G M Otter; F M Sirotnak
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

4.  Effective combination therapy of metastatic murine solid tumors with edatrexate and the vinca alkaloids, vinblastine, navelbine and vindesine.

Authors:  G M Otter; F M Sirotnak
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.